Stock Research for PTCT

PTCT
Current Price

$25.5100


Latest Update: 2018-02-23 16:00:00

High
$ 25.5300
Low
$ 25.5000
Close
$ 25.5200
Volume
50921
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

PTCT Stock Chart & Research Data

The PTCT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PTCT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


PTCT Due diligence Resources & Stock Charts

The PTCT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PTCT Detailed Price Forecast - CNN Money CNN View PTCT Detailed Summary - Google Finance
Yahoo View PTCT Detailed Summary - Yahoo! Finance Zacks View PTCT Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View PTCT Trends & Analysis - Trade-Ideas Barrons View PTCT Major Holders - Barrons
NASDAQ View PTCT Call Transcripts - NASDAQ Seeking View PTCT Breaking News & Analysis - Seeking Alpha
Spotlight View PTCT Annual Report - CompanySpotlight.com OTC Report View PTCT OTC Short Report - OTCShortReport.com
TradeKing View PTCT Fundamentals - TradeKing Charts View PTCT SEC Filings - Bar Chart
WSJ View Historical Prices for PTCT - The WSJ Morningstar View Performance/Total Return for PTCT - Morningstar
MarketWatch View the Analyst Estimates for PTCT - MarketWatch CNBC View the Earnings History for PTCT - CNBC
StockMarketWatch View the PTCT Earnings - StockMarketWatch MacroAxis View PTCT Buy or Sell Recommendations - MacroAxis
Bullish View the PTCT Bullish Patterns - American Bulls Short Pains View PTCT Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View PTCT Stock Mentions - StockTwits PennyStocks View PTCT Stock Mentions - PennyStockTweets
Twitter View PTCT Stock Mentions - Twitter Invest Hub View PTCT Investment Forum News - Investor Hub
Yahoo View PTCT Stock Mentions - Yahoo! Message Board Seeking Alpha View PTCT Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for PTCT - SECform4.com Insider Cow View Insider Transactions for PTCT - Insider Cow
CNBC View PTCT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PTCT - OTC Markets
Yahoo View Insider Transactions for PTCT - Yahoo! Finance NASDAQ View Institutional Holdings for PTCT - NASDAQ


Stock Charts

FinViz View PTCT Stock Insight & Charts - FinViz.com StockCharts View PTCT Investment Charts - StockCharts.com
BarChart View PTCT Stock Overview & Charts - BarChart Trading View View PTCT User Generated Charts - Trading View


Latest Financial News for PTCT

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2017 Financial Results
Posted on Wednesday February 21, 2018

SOUTH PLAINFIELD, N.J. , Feb. 21, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end ...


PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs
Posted on Tuesday February 20, 2018

SOUTH PLAINFIELD, N.J., Feb. 20, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior position and denied PTC's appeal of the Complete Response Letter in relation to the New Drug Application (NDA) for ataluren. In its letter, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway.


PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy
Posted on Tuesday February 13, 2018

SOUTH PLAINFIELD, N.J., Feb. 13, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) is delighted to announce the launch of the fourth annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne Muscular Dystrophy (DMD). The STRIVE Awards provide funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates.


PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Posted on Friday February 09, 2018

SOUTH PLAINFIELD, N.J. , Feb. 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2018 RBC Capital Markets Global ...


PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare ...
PR Newswire (press release) - Feb 9, 2018
PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology.
PTC Therapeutics Inc. (PTCT) Plunges 6.48% on February 08 - Equities.com
This is what analysts have to say about PTC Therapeutics, Inc. (NASDAQ:PTCT ... - BZ Weekly

Oppenheimer & Co. Inc. Buys 2400 Shares of PTC Therapeutics, Inc. (PTCT)
Dispatch Tribunal - Jan 27, 2018
PTC Therapeutics logo Oppenheimer & Co. Inc. boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 15.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission.
A Comparison of Top Movers: Editas Medicine, Inc. (EDIT), PTC Therapeutics ... - StockNewsGazette
Is Buying PTC Therapeutics, Inc. (PTCT) Here a Winning Strategy? - WeeklyHub

PTC Therapeutics (PTCT) Says FDA Denied Appeal of CRL in Relation to NDA for ...
StreetInsider.com - Feb 20, 2018
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior position and denied PTC's appeal of the Complete Response Letter in relation to the New Drug ...
Financially Devastating or Fantastic? – PTC Therapeutics, Inc. (PTCT), AVEO ... - StockNewsGazette

Pinnacle Associates Ltd. Lowers Holdings in PTC Therapeutics, Inc. (PTCT)
Newburgh Gazette - 4 hours ago
Coatue Management Llc sold 1.08 million shares as the company's stock declined 18.04% while stock markets rallied. In related news, CEO Stuart Walter Peltz sold 2,230 shares of the firm's stock in a transaction dated Friday, January 5th.
Finally Time For Investors to Buy? JP Morgan Upgrades PTC Therapeutics (NASDAQ ... - BZ Weekly

Enter a stock symbol to view the stock details.